Avanti launches bionano company

Avanti Therapeutics launched a new bionanotechnology company for targeted drug delivery called Chikujee Therapeutics. Chikujee will use Avanti's drug delivery technology to enhance the performance of drugs, specifically anti-cancer drugs. The first drug classes the company will focus on are taxols (Paclitaxel and Docetaxel) and camptothecin for chemotherapy. Chikujee is Avanti's third early-stage company.

- here's the release

Related Articles:
Biotech says nano-device can directly target cancer cells. Report
MD considers funds for growing nano-biotech field. Report
Venture capitalists bet big on nanotechnology. Report
Nanotech is promising, but faces hurdles. Report